PRESS RELEASE



2003-05-12

Box 5513, SE-114 85 Stockholm (Storgatan 19), Sweden. Tel: +46 (8) 783 85 00. Fax: +46 (8) 662 90 93. www.swedishtrade.com, www.biosweden.org

Leading Swedish Biotechnology at BIO2003 in Washington

The Swedish tradition of drug discovery and development is one of the strongest in the world. Following the growth of Pharmacia and AstraZeneca into global pharma companies, a new breed of companies is emerging. A number of the most successful companies will offer their research and technology to new partners, clients and investors at the BIO2003 Annual Convention and Exhibition in Washington, 22-25 June.

Companies: Looking for: Active Biotech Active Biotech is seeking partnerships for a novel oral immunomodulatory drug (SAIK-MS) aimed for the treatment of multiple sclerosis, as well as for an oral drug (TASQ) designed for the treatment of prostate cancer. The company is also seeking collaboration partners in relation to a novel concept (TTS) for immunotherapy of cancer. cecilia.hofvander@activebiotech.com Affibody Seeking partnerships with pharmaceutical companies for target identification and validation using Affibody's proprietary technology. Marten.osterlund@affibody.com **Bioventia** Bioventia is acting as a link between innovations, financing and competent management and is currently looking for international strategic partnerships. lena.lebel@bioventia.com **Biovitrum** Biovitrum is actively looking for in-licensing partners to strengthen the project portfolio in our core therapeutic areas: type 2 diabetes, obesity and oncology. Biovitrum also has expert knowledge and capabilities in process development and GMP manufacturing of recombinant protein drugs, which is offered to Biovitrum's partners and customers. lars.bjork@biovitrum.com **Global Genomics** Introducing Tangerine, a solution for gene expression profiling that identifies virtually all active genes in a given sample. The technology can be applied within drug discovery to support target and lead identification and validation through to analysis during clinical trials. ulf@globalgenomics.com Karo Bio Product opportunities are Selective GR modulators/ Anti-inflammatory therapeutics, Selective AR modulators/ Prostate cancer, Selective TR modulators, HRT, SERMs, Dxr compound series/ Antibacterial, IspB compound series/ Antibacterial, 10 Biokey® assays/ Antibacterial. lars.ohman@karobio.se Melacure Therapeutics Seeking partnerships with leading companies in therapeutic areas relevant to the melanocortin receptor field (MC1, MC3, MC4 and MC5) with opportunities in inflammation, obesity, diabetes and sexual dysfunction. ulf.vallgren@melacure.com NeuroNova is seeking strategic partnerships with pharmaceutical and biotechnology companies with an NeuroNova international presence in order to further the clinical development and commercialisation of its innovative therapies within its Therapeutic Neurogenesis and its Cell Transplantation Therapy programs. iohan.haggblad@neuronova.com Other Swedish organizations also represented at BIO2003 are: Invest in Sweden Agency www.isa.se Karolinska Institute www.ki.se **Biotech Forum** www.biotechforum.org www.stockholmuppsalabioregion.com Stockholm Uppsala Bioregion Swedish Agency for Innovation Systems

www.vinnova.se www.swedishtrade.com www.investin.uppsala.se For more information on Swedish Biotechnology, see www.biosweden.org.

For more information, contact:

Swedish Trade Council

UppsalaBIO

Mr. David Ernstsson, Director Swedish Bioscience Programme, Swedish Trade Council, Cell: +46 708 85 87 01, E-mail: david.ernstsson@swedishtrade.se

Ms Clare Hobby, Swedish Bioscience Programme, Swedish Trade Council / Los Angeles, Cell: +1 312 925 6560, E-mail: clare.hobby@swedishtrade.se